JC09 Rec'd PCT/PTO u2 AUG 2005.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Lutz HILBRICH, et al. U.S. Appln. No. : Not Yet Assigned Confirmation No. : Not Yet Assigned U.S. Filing Date : Not Yet Assigned Title of Invention : Use of dipyridamole in comangiotensin II antagonist for s Attny. Docket No. : 1/1461 PCT		-
Mail Stop Amendment Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450		
August 2, 2005 TRANSMITTAL LETTER FOR INFORM	AATION DISCL	OSURE STATEMENT
Sir:		
Transmitted herewith concerning the subject app Statement (Form 1449A/B) under 37 C.F.R. §§1 hereinbelow.		
1.97(b). This Statement is being fidate of a national application other than a contin §1.53 (d); ii) within three (3) months of the date 37 C.F.R. §1.491 in an international application; on the merits; or iv) before the mailing of a first continued examination under 37 C.F.R. §1.114.	ued prosecution a of entry of the na iii) before the ma	pplication under 33 C.F.R. tional stage as set forth in ailing of a first Office action
1.97(c). This Statement is being find C.F.R. §1.97(b), but before the mailing date of: in notice of allowance under 37 C.F.R. §1.311, or in the application. This Statement is being according) a final action unii) an action that o	nder 37 C.F.R. §1.113, ii) a
A statement as specified in 37 C.	F.R. §1.97(e) [see	e below]; or
The fee set forth in 37 C.F.R. §1.	17(p).	

		nmissioner is hereby authorized to charge payment of the forth in 37 C.F.R. §1.17(p) to Deposit Account No.
5 1.97(c)) but on or before payn nt as specified in 37 C.	tement is being filed after the period specified in 37 C.F.R. nent of the issue fee. This Statement is accompanied by a F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R.
1	1.97(e).	
C	statement was first cite counterpart foreign app	formation contained in the instant information disclosure d in any communication from a foreign patent office in a discalation not more than three (3) months prior to the filing of disclosure statement; or
f r i §	statement was cited in foreign application, and making reasonable inquinformation disclosure	rmation contained in the instant information disclosure a communication from a foreign patent office in a counterpart d, to the knowledge of the person signing this certification after airy, no item of information contained in the instant statement was known to any individual designated in 37 C.F.R. ee (3) months prior to the filing of the instant information
[The fee set fort	n in 37 C.F.R. §1.17(p).
		nmissioner is hereby authorized to charge payment of the forth in 37 C.F.R. §1.17(p) to Deposit Account No.
disclosu counterp in sectio	re statement was cited part application, which	m of information contained in the accompanying information in a communication from a foreign patent office in a communication was not received by any individual designated irty (30) days prior to the filing of the accompanying ent.

10/544239 JC09 Rec'd PCT/PTQ 02 AUG 2005

The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,

Andrea D. Small

Attorney for Applicant(s)

Reg. No. 54,859

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road, P.O. Box 368 Ridgefield, CT 06877 Tel: (203) 798-4816 Certificate of Mailing

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop Amendment Commissioner For Patents P. O. Box 1450 Alexandria, VA 22313-1450

on August 2, 2005.

Andrea D. Small, Reg. No. 54,859

10/544239

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are require Substitute for form 1449A/PTO				mplete if Known		
000	State of form 1110/01 10			Application Number	Not Yet Assigned	
IN	IFORMATION DIS	CLC	SURE	Filing Date	Not Yet Assigned	
STATEMENT BY APPLICANT		First Named Inventor	Lutz HILBRICH			
		Art Unit	Not Yet Assigned			
	(Use as many sheets as ne	ecessarv)	Examiner Name	Not Yet Assigned	
heet	1	of	2	Attorney Docket Number	1/1461 PCT	

			U.S. PATENT D	OCUMENTS		
Examiner Cite Initials* No.1		Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	
		Number-Kind Code ^{2 (if known)}			Figures Appear	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		US-				
		US-				
		US-				
,		US-				
		US-				
		US-				
······································		US-				
		us-				
		US-				
		US-				
		US-				
		US-				

		FOREIG	N PATENT DOC	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ 'Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		WO 01/30353	05-03-2001	Boehringer Ingelheim Pharma KG		
		WO 01/15673	03-08-2001	Aventis Pharma Deutschland GmbH	***************************************	

<u>.</u>	ļ				***************************************	

Examiner	Date	
Signature	Considered	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

10/544239 JC09 Rec'd PCT/PTO 02 AUG 2005

Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known		
Substitute for form 177057715				Application Number	Not Yet Assigned
INFOR	MATION D	ISCLO	SURE	Filing Date	Not Yet Assigned
STATEMENT BY APPLICANT		First Named Inventor	Lutz HILBRICH		
				Art Unit	Not Yet Assigned
(Use as many sheets as necessary)		Examiner Name	Not Yet Assigned		
Sheet	2	of	2	Attorney Docket Number	1/1461 PCT

		NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1						
		"Aggrenox: A Combination of Antiplatelet Drugs for Stroke Prevention", The Medical Letter on Drugs and Therapeutics, Vol. 42, Issue 1071, 2000, pp 11-12					
		A.J. SCHEEN "La combinaison fixe dipyridamole - acide acetylsalicylique (Aggrenox) Extended-Release Dipyridamole/Aspirin (Aggrenoxarhou)", Revue Medicale De Liege, Vol. 55, no. 10, 2000, pgs 957-959					
		A.I. MALININ, et al. "Aggrenox (Extended-Release Dipyridamole and Low-Dose Aspirin in Combination): Protecting Platelets from Excessive Activation in Patients with Vascular Events", Heart Drug, Vol. 2, No. 2, 2002, pgs 93-104					
		Boehringer Ingelheim News, 'Online!' "Largest-Ever Stroke Prevention Trial Launched" 2003					
	•••••						
	•••••••		ļ				
	***************************************		ļ				
			<u></u>				
Examiner		Date					

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Signature

Considered

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.